- Conditions
- Prostate Cancer
- Interventions
- Decipher® Testing
- Other
- Lead sponsor
- H. Lee Moffitt Cancer Center and Research Institute
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 240 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2026
- U.S. locations
- 3
- States / cities
- Bay Pines, Florida • Tampa, Florida
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 145–168
of 439
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Recurrent Primary Cutaneous T-Cell Non-Hodgkin Lymphoma, Stage I Mycosis Fungoides and Sezary Syndrome AJCC v7, Stage II Mycosis Fungoides and Sezary Syndrome AJCC v7
- Interventions
- Carmustine, Laboratory Biomarker Analysis, O6-Benzylguanine
- Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 19 Years and older
- Enrollment
- 17 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2014
- U.S. locations
- 4
- States / cities
- Detroit, Michigan • Cleveland, Ohio • Columbus, Ohio
- Conditions
- Mantle Cell Lymphoma, Lymphoma, Mantle Cell
- Interventions
- EPOCH-R, GM-CSF, Idiotype vaccine
- Drug · Biological
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 26 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2000 – 2021
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Recurrent Prostate Cancer
- Interventions
- Verteporfin, SpectraCure P18 System
- Drug · Device
- Lead sponsor
- SpectraCure AB
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 66 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2027
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Vertebral Metastasis
- Interventions
- Conformal High Dose Intensity Modulated Radiation Therapy
- Radiation
- Lead sponsor
- Ronald McGarry
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 14 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2016
- U.S. locations
- 1
- States / cities
- Lexington, Kentucky
- Conditions
- Prostate Cancer
- Interventions
- docetaxel, leuprolide acetate, radiation therapy
- Drug · Radiation
- Lead sponsor
- UNC Lineberger Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years to 120 Years · Male only
- Enrollment
- 23 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2012
- U.S. locations
- 2
- States / cities
- Chapel Hill, North Carolina • Raleigh, North Carolina
- Conditions
- Herpes Simplex
- Interventions
- Lower dose formulation of HSV vaccine (GSK4108771A), Low dose formulation of HSV vaccine (GSK4108771A), Medium dose formulation of HSV vaccine (GSK4108771A), High dose formulation of HSV vaccine (GSK4108771A), Placebo (saline)
- Biological · Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years to 40 Years
- Enrollment
- 17 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021
- U.S. locations
- 2
- States / cities
- Lenexa, Kansas • Rochester, New York
- Conditions
- Prostate Cancer, Prostatic Cancer, Prostate Neoplasms, Prostatic Neoplasms, Cancer of the Prostate
- Interventions
- CyberKnife Stereotactic Radiosurgery
- Radiation
- Lead sponsor
- Accuray Incorporated
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 379 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2021
- U.S. locations
- 23
- States / cities
- Phoenix, Arizona • La Jolla, California • Newport Beach, California + 17 more
- Conditions
- Prostate Adenocarcinoma, Stage I Prostate Cancer American Joint Committee on Cancer (AJCC) v8, Stage II Prostate Cancer AJCC v8, Stage IIA Prostate Cancer AJCC v8, Stage IIB Prostate Cancer AJCC v8, Stage IIC Prostate Cancer AJCC v8
- Interventions
- Discussion, Hypofractionated Radiation Therapy, Laboratory Biomarker Analysis, Quality-of-Life Assessment, Questionnaire Administration, Stereotactic Body Radiation Therapy
- Procedure · Radiation · Other
- Lead sponsor
- Jonsson Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 208 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2028
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Recurrent Prostate Carcinoma
- Interventions
- Computed Tomography, Fluciclovine F18, Gallium Ga 68-labeled PSMA-11, Laboratory Biomarker Analysis, Positron Emission Tomography
- Procedure · Drug · Other
- Lead sponsor
- Jonsson Comprehensive Cancer Center
- Other
- Eligibility
- 19 Years and older · Male only
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Prostate Cancer (CRPC)
- Interventions
- Not listed
- Lead sponsor
- Jonsson Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2036
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Prostate Cancer
- Interventions
- Antigen direct immunotherapy: PROSTVAC-V, Antigen direct immunotherapy: PROSTVAC-F, MSB0011359C (M7824), Antigen direct immunotherapy: CV301, CT scan of chest, CT scan of abdomen/pelvis, MRI, PSMA, Bone scan
- Biological · Drug · Diagnostic Test
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2024
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Prostate Cancer
- Interventions
- Questioners, blood specimens, prostate tissue specimens
- Other
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 35 Years and older · Male only
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2011
- U.S. locations
- 2
- States / cities
- Los Angeles, California • New York, New York
- Conditions
- Biochemically Recurrent Prostate Carcinoma, Metastatic Prostate Carcinoma, Prostate Adenocarcinoma, Stage IVB Prostate Cancer AJCC v8
- Interventions
- 3-Dimensional Conformal Radiation Therapy, Apalutamide, Computed Tomography, Degarelix, External Beam Radiation Therapy, Fluciclovine F18, Goserelin Acetate, Intensity-Modulated Proton Therapy, Intensity-Modulated Radiation Therapy, Leuprolide Acetate, Magnetic Resonance Imaging, Positron Emission Tomography, Quality-of-Life Assessment, Questionnaire Administration, Relugolix, Stereotactic Body Radiation Therapy, Triptorelin, Volume Modulated Arc Therapy
- Radiation · Drug · Procedure + 1 more
- Lead sponsor
- ECOG-ACRIN Cancer Research Group
- Network
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 804 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2032
- U.S. locations
- 341
- States / cities
- Anchorage, Alaska • Fairbanks, Alaska • Phoenix, Arizona + 240 more
- Conditions
- Substance Use Disorders, Opioid Use Disorder, Alcohol Use Disorder, Cocaine Use Disorder, Methamphetamine-dependence
- Interventions
- EDITOR (CBOT with olfactory stimulants, OFC tasks & remote monitoring of treatment compliance), CBOT with olfactory stimulants & OFC tasks, CBOT Sham
- Combination Product
- Lead sponsor
- Evon Medics LLC
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 300 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 3
- States / cities
- Washington D.C., District of Columbia • Rockville, Maryland
- Conditions
- Prostate Cancer
- Interventions
- Fluciclovine PET/CT
- Drug
- Lead sponsor
- OHSU Knight Cancer Institute
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 1
- States / cities
- Portland, Oregon
- Conditions
- Prostate Cancer
- Interventions
- Cabazitaxel, Intensity Modulated Radiation Therapy (IMRT), Anti-Androgen Therapy: Bicalutamide, Luteinizing Hormone-Releasing Hormone (LHRH) Agonist
- Drug · Radiation · Genetic
- Lead sponsor
- Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2020
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Prostatic Neoplasms, Prostate Cancer
- Interventions
- 18F DCFBC, Sodium (Na)18F positron emission tomography (PET)/computed tomography (CT)
- Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years to 99 Years · Male only
- Enrollment
- 116 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2018
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Prostate Cancer
- Interventions
- recombinant interferon alfa-2b, docetaxel, estramustine phosphate sodium, isotretinoin, polyacrylamide gel electrophoresis, protein expression analysis, immunohistochemistry staining method
- Biological · Drug · Genetic + 1 more
- Lead sponsor
- University of Medicine and Dentistry of New Jersey
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2007
- U.S. locations
- 1
- States / cities
- New Brunswick, New Jersey
- Conditions
- Recurrent Prostate Adenocarcinoma, Stage IVB Prostate Cancer AJCC v8, Castration-Sensitive Prostate Cancer, Metastatic Hormone-sensitive Prostate Cancer (mHSPC), Prostate Cancer, Prostate Adenocarcinoma, Adenocarcinoma of the Prostate, Localized Prostate Carcinoma, Metastatic Prostate Cancer, Metastatic Prostate Adenocarcinoma, Advanced Prostate Cancer, Advanced Prostate Adenocarcinoma
- Interventions
- Abiraterone Acetate, Biospecimen Collection, Leuprolide Acetate, Lutetium Lu 177 Vipivotide Tetraxetan, Prednisone, PSMA PET-CT Scan, Quality-of-Life Assessment, Single Photon Emission Computed Tomography
- Drug · Procedure · Other
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 202 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Prostate Cancer
- Interventions
- calcifidiol
- Drug
- Lead sponsor
- US Department of Veterans Affairs
- Federal
- Eligibility
- Male only
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1999 – 2002
- U.S. locations
- 1
- States / cities
- Miami, Florida
- Conditions
- Prostate Cancer
- Interventions
- Prolaris
- Behavioral
- Lead sponsor
- Myriad Genetic Laboratories, Inc.
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 1,511 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2022
- U.S. locations
- 12
- States / cities
- San Diego, California • West Haven, Connecticut • Tampa, Florida + 9 more
- Conditions
- Recurrent Prostate Carcinoma
- Interventions
- High-Dose Rate Brachytherapy, Hyperthermia Treatment, Laboratory Biomarker Analysis
- Radiation · Procedure · Other
- Lead sponsor
- Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2025
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Borderline Resectable Pancreatic Ductal Adenocarcinoma, Resectable Pancreatic Adenocarcinoma, Stage I Pancreatic Cancer AJCC v8, Stage II Pancreatic Cancer AJCC v8, Stage III Pancreatic Cancer AJCC v8
- Interventions
- Biopsy, Biospecimen Collection, Cisplatin, Computed Tomography, Gemcitabine, Magnetic Resonance Imaging, Nab-paclitaxel, Pancreatic Surgical Procedure
- Procedure · Drug
- Lead sponsor
- Georgetown University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 2
- States / cities
- Washington D.C., District of Columbia • Atlanta, Georgia